CXCR2: C-X-C chemokine receptor type 2
Receptor for interleukin-8 which is a powerful neutrophil chemotactic factor.
- Drugs that act on it: 5
- Approved: 0
- In phases 1 to 3: 5
- Sponsors: 3
Who is on it, and how far along
Every drug ChEMBL records acting on CXCR2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 5
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Dompé Farmaceutici240%
- GSK240%
- Merck & Co. (MSD)120%
| Ladarixin | Phase 3 | Dompé Farmaceutici | Small molecule | ModulatorInterleukin-8 receptor B modulator | 1 |
| Reparixin | Phase 3 | Dompé Farmaceutici | Small molecule | ModulatorInterleukin-8 receptor B modulator | 1 |
| Danirixin | Phase 2 | GSK | Small molecule | Antagonist | 0 |
| Elubrixin | Phase 2 | GSK | Small molecule | Antagonist | 0 |
| Navarixin anhydrous | Phase 2 | Merck & Co. (MSD) | Small molecule | Antagonist | 0 |
| Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | Reparixin | Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | Apr 28, 2023 |
| Ladarixin With Sotorasib in Advanced NSCLC | Ladarixin | Phase 1 | Recruiting | NYU Langone Health | Apr 18, 2023 |
- WHIM syndrome 20.59
- Ulcerative colitis0.53
- Inflammatory bowel disease0.45
- Psoriasis0.37
- Autosomal recessive severe congenital neutropenia due to CXCR2 deficiency0.37
- Crohn disease0.36
- Sclerosing cholangitis0.35
- Ankylosing spondylitis0.35
- Type 1 diabetes mellitus0.30
- COVID-190.15
- Breast cancer0.14
- Triple-negative breast carcinoma0.13
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2434, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P25025, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets